metricas
covid
Buscar en
Acta Otorrinolaringológica Española
Toda la web
Inicio Acta Otorrinolaringológica Española Association between maximum standarised uptake value (SUV) and local control in ...
Journal Information
Vol. 74. Issue 4.
Pages 211-218 (July - August 2023)
Share
Share
Download PDF
More article options
Vol. 74. Issue 4.
Pages 211-218 (July - August 2023)
Original article
Association between maximum standarised uptake value (SUV) and local control in patients with oropharyngeal carcinoma treated with radiotherapy
Asociación entre el standarized uptake value (SUV) máximo y el control local en pacientes con carcinoma de orofaringe tratados con radioterapia
Anna Holgadoa, Xavier Leóna,b,c,
Corresponding author
aholgado@santpau.cat

Corresponding author.
, Miquel Quera,b, Valle Camachod, Alejando Fernándezd
a Servicio de Otorrinolaringología-->, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
b Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
c UVIC-->, Universitat Central de Catalunya, Vic, Spain
d Servicio de Medicina Nuclear-->, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (3)
Table 1. Characteristics of patients included in the study.
Table 2. Multivariate analysis considering local recurrence-free survival as the dependent variable.
Table 3. Studies which evaluated the prognostic capacity of SUVmax in patients with oropharyngeal carcinomas.
Show moreShow less
Additional material (1)
Abstract
Objective

To analyse the prognostic ability of the maximum standardised uptake value (SUVmax) on local disease control in patients with oropharyngeal carcinoma treated with radiotherapy.

Material and methods

Retrospective study of 105 patients with oropharyngeal carcinomas treated with radiotherapy, including chemo- and bio-radiotherapy, and who had a PET-CT scan prior to the start of treatment.

Result

Patients with a SUVmax value higher than 17.2 at the primary tumour site had a significantly higher risk of local recurrence. The 5-year local recurrence-free survival for patients with SUVmax less than or equal to 17.2 (n = 71) was 86.5% (95% CI 78.2–94.7 %), and for patients with SUVmax greater than 17.2 (n = 34) it was 55.8% (95% CI 36.0–75.6 %) (P = 0.0001). This difference in local control was maintained regardless of patients' HPV status. Specific survival was similarly lower for patients with a SUV greater than 17.2. The 5-year specific survival for patients with SUVmax greater than 17.2 was 39.5% (95% CI: 20.6–58.3 %), significantly shorter than that of patients with SUVmax equal to or less than 17.2, which was 77.3% (95% CI: 66.9–87.6 %) (P = 0.0001).

Conclusions

Patients with oropharyngeal carcinomas treated with radiotherapy with a SUVmax greater than 17.2 at the level of the primary tumour site had a significantly higher risk of local recurrence.

Keywords:
Prognostic ability
SUVmax
Oropharyngeal carcinoma
Radiation therapy
Resumen
Objetivo

Analizar la capacidad pronóstica del valor de captación estandarizado máximo (SUVmáx) en el control local de la enfermedad en pacientes con carcinomas de orofaringe tratados con radioterapia.

Material y métodos

Estudio retrospectivo de 105 pacientes con carcinomas de orofaringe tratados con radioterapia, incluyendo tratamientos con quimio y bio-radioterapia, y que contaron con una exploración PET-TC previa al inicio del tratamiento.

Resultado

Los pacientes con un valor del SUVmáx superior a 17,2 en la localización primaria del tumor tuvieron un riesgo significativamente más elevado de recidiva local. La supervivencia libre de recidiva local a los 5 años para los pacientes con un SUVmáx inferior o igual a 17,2 (n = 71) fue del 86,5% (IC 95%: 78,2–94,7%), y para los pacientes con un SUVmáx superior a 17,2 (n = 34) fue del 55,8% (IC 95%: 36,0–75,6%) (P = 0,0001). Esta diferencia en control local se mantuvo independientemente de estatus VPH de los pacientes. La supervivencia específica fue igualmente inferior para los pacientes con un SUV superior a 17,2. La supervivencia específica a los 5 años para los pacientes con un SUVmáx superior a 17,2 fue del 39,5% (IC 95%: 20,6–58,3%), significativamente más reducida que la de los pacientes con SUVmáx igual o inferior a 17,2, que fue del 77,3% (IC 95%: 66,9–87,6%) (P = 0,0001).

Conclusiones

Los pacientes con carcinomas de orofaringe tratados con radioterapia con un SUVmáx superior a 17,2 a nivel de la localización primaria del tumor tuvieron un riesgo significativamente más elevado de recidiva local.

Palabras clave:
Capacidad pronóstica
SUVmáx
Carcinoma orofaringe
Radioterapia

Article

These are the options to access the full texts of the publication Acta Otorrinolaringológica Española
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Acta Otorrinolaringológica Española

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos